FSD Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for FSD Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth56.7%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Apr 13
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Dec 17
We're Keeping An Eye On FSD Pharma's (CSE:HUGE) Cash Burn Rate

Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

Aug 25
Here's Why We're Watching FSD Pharma's (CSE:HUGE) Cash Burn Situation

How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

Feb 13
How Many FSD Pharma Inc. (CSE:HUGE) Shares Did Insiders Buy, In The Last Year?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FSD Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

CNSX:HUGE - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2023N/A-18-11-11N/A
9/30/2023N/A-23-16-16N/A
6/30/2023N/A-29-22-22N/A
3/31/2023N/A-31-28-28N/A
12/31/2022N/A-27-29-28N/A
9/30/2022N/A-27-26-26N/A
6/30/2022N/A-25-23-23N/A
3/31/2022N/A-30-21-20N/A
12/31/2021N/A-34-21-21N/A
9/30/2021N/A-32-22-21N/A
6/30/2021N/A-39-22-22N/A
3/31/2021N/A-30-20-19N/A
12/31/2020N/A-28-19-19N/A
9/30/2020N/A-36-18-17N/A
6/30/2020N/A-35-15-15N/A
3/31/2020N/A-41-17-16N/A
12/31/2019N/A-34-14-14N/A
9/30/20190-38-14-14N/A
6/30/20190-25-20-19N/A
3/31/20190-16-16-16N/A
12/31/2018N/A-17-17-14N/A
9/30/20180-2-19-11N/A
6/30/20180-7-11-3N/A
3/31/20180-4-10-1N/A
12/31/20170-3-60N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if HUGE's forecast earnings growth is above the savings rate (2%).

Earnings vs Market: Insufficient data to determine if HUGE's earnings are forecast to grow faster than the Canadian market

High Growth Earnings: Insufficient data to determine if HUGE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if HUGE's revenue is forecast to grow faster than the Canadian market.

High Growth Revenue: Insufficient data to determine if HUGE's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if HUGE's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.